| 摘要 |
The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions. |
| 申请人 |
NOVARTIS;IRM LLC |
发明人 |
BOETTCHER,BRIAN,R.;CAPLAN,SHARI,L.;CELLITTI,SUZAN.E;DANIELS,DOUGLAS,S.;HAMAMATSU,NORIO;GEIERSTANGER,BERNHARD,HUBERT;LICHT,STUART;LOEW,ANDREAS;WELDON,STEPHEN,GRAIG |
